123 related articles for article (PubMed ID: 38508431)
1. Bushen Formula promotes the decrease of HBsAg levels in patients with CHB by regulating Tfh cells and B-cell subsets.
Ji L; Wei J; Zhang R; Zhang X; Gao Y; Fang M; Yu Z; Cao L; Gao Y; Li M
J Ethnopharmacol; 2024 Jun; 328():118072. PubMed ID: 38508431
[TBL] [Abstract][Full Text] [Related]
2. Beneficial Effects of Bushen Formula Combined with Enticavir on Chronic Hepatitis B Patients with Suboptimal Response to Enticavir by Regulating B-Cell Differentiation.
Li M; Zhou ZH; Bao T; Zhang X; Zhu XJ; Jin SG; Gao YT; Sun XH; Gao YQ
Cell Physiol Biochem; 2018; 48(2):633-643. PubMed ID: 30025397
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients.
Ji LS; Gao QT; Guo RW; Zhang X; Zhou ZH; Yu Z; Zhu XJ; Gao YT; Sun XH; Gao YQ; Li M
J Immunol Res; 2019; 2019():8983903. PubMed ID: 30766891
[TBL] [Abstract][Full Text] [Related]
4. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
[TBL] [Abstract][Full Text] [Related]
6. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
7. Circulating PD-1
Zhang L; Li H; Ren H; Hu P
Mol Immunol; 2018 Nov; 103():270-278. PubMed ID: 30340072
[TBL] [Abstract][Full Text] [Related]
8. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
9. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
Luo H; Tan G; Hu X; Li Y; Lei D; Zeng Y; Qin B
Virol J; 2023 Jul; 20(1):161. PubMed ID: 37475028
[TBL] [Abstract][Full Text] [Related]
10. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
11. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
12. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
13. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
[TBL] [Abstract][Full Text] [Related]
14. LAG3
Pang XQ; Li X; Zhu WH; Huang RK; Mo ZS; Huang ZX; Zhang Y; Xie DY; Gao ZL
Antiviral Res; 2023 May; 213():105592. PubMed ID: 37004734
[TBL] [Abstract][Full Text] [Related]
15. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
16. Beneficial therapeutic effect of Chinese herbal Bushen formula on CHB patients with mildly elevated alanine aminotransferase by down-regulating CD4+CD25+T cells.
Li M; Sun XH; Zhou ZH; Yu Z; Jin SG; Zhu XJ; Gao YQ
J Ethnopharmacol; 2013 Mar; 146(2):614-22. PubMed ID: 23395622
[TBL] [Abstract][Full Text] [Related]
17. T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production.
Liu Y; Hu X; Hu X; Yu L; Ji H; Li W; Cai Y; Cheng G; Jiang Y
J Gastroenterol; 2022 Jan; 57(1):30-45. PubMed ID: 34988689
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.
Li M; Zhang L; Xie S; Sun F; Zeng Z; Deng W; Jiang T; Bi X; Lin Y; Yang L; Lu Y; Shen G; Liu R; Wu S; Chang M; Hu L; Dong J; Yi W; Xie Y
Front Immunol; 2022; 13():892031. PubMed ID: 35603222
[TBL] [Abstract][Full Text] [Related]
20. Follicular Helper T (T
Ayithan N; Tang L; Tan SK; Chen D; Wallin JJ; Fletcher SP; Kottilil S; Poonia B
Front Immunol; 2021; 12():735913. PubMed ID: 34512670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
